Picture this.
You lose 50 pounds on a weekly injection.
You feel amazing.
Then, slowly, you stop.
Not because it didn't work — but because you're tired of the needle, the cost, the routine.
Within a year, more than half of GLP-1 patients quit.
And most of them regain the weight.
That's the problem Novo Nordisk just placed a bet on solving.
Vivani Medical, a small biotech, has been quietly building something strange.
A titanium implant, smaller than a matchstick, placed under the skin.
Filled with semaglutide — the same drug inside Wegovy and Ozempic.
No injections. No daily pills.
👉 Just twice a year. Maybe, one day, once a year.
Novo just signed an agreement to evaluate it.
Not a licensing deal. Not exclusive.
But a serious signal from the world's biggest weight-loss drugmaker.
No pumps. No batteries. No moving parts.
Just a membrane with millions of microscopic "straws" that release the drug at a slow, steady trickle.
Vivani's CEO Adam Mendelsohn put it bluntly: "What these drugs are capable of is not being carefully taken advantage of right now."
Early rat data showed ~20% weight loss over 6 months.
Promising. But rats aren't people.
Human trials — just 20 participants — don't even start until mid-2026.
Doctors are cautiously intrigued, not sold.
"I'm probably overall very skeptical, but I'm happy to be proven wrong," said one UC Davis obesity specialist.
Others worry about cost, insurance coverage, and whether telehealth-first patients on Ro or Hims & Hers can even access an in-office procedure.
This isn't just about one implant.
It's Novo hedging against a market where Eli Lilly's rival drugs are eating into its lead — and where the real battle isn't losing weight anymore.
It's keeping it off.
Because a $100 billion+ obesity drug market means nothing…
…if half the patients walk away within a year.
The company that solves adherence — not just efficacy — might just win obesity medicine's next decade.
That's all for now!
